Celon Pharma’s PDE10A inhibitor has reduced involuntary movements in a phase 2 trial of individuals with Parkinson’s disease. The Polish biotech tested two daily doses of the drug, dubbed CPL’36, in ...
SALT LAKE CITY — When performing surgery on the retina — one of the smallest, most delicate parts of the human body — the margin of error is virtually ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback